@phdthesis{vonBosse2022,
  author    = {von Bosse, Felix},
  title     = {Risikofaktoren der venoarteriellen extrakorporalen Membranoxygenierung bei Post-Kardiotomie-Patienten},
  doi       = {10.25972/OPUS-25819},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-258198},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2022},
  abstract  = {Die extrakorporale Membranoxygenierung ist ein seit Jahrzehnten etabliertes Verfahren, Patienten trotz kardialem und/oder pulmonalem Versagen ein zeitbegrenztes {\"U}berleben zu erm{\"o}glichen. Obgleich sich an den Grundz{\"u}gen der Herangehensweise bis heute wenig ver{\"a}ndert hat, konnte diese Hochrisikotherapie mithilfe der Entwicklung blutschonenderer Materialien und der Verwendung verbesserter Pumpen und Oxygenatoren zunehmend effizienter gestaltet werden. Durch eine {\"U}berlebensanalyse aller ECMO-Patienten der Datenbank der Klinik f{\"u}r Tho-rax-, Herz- und Thorakale Gef{\"a}ßchirurgie des Universit{\"a}tsklinikums W{\"u}rzburg zwischen 2015 und 2018 (172 F{\"a}lle) sollten unabh{\"a}ngige Risikofaktoren f{\"u}r ein negatives Outcome der Therapie identifiziert werden. Insbesondere den Laborparametern w{\"a}hrend der ersten 72 Stunden am System galt hierbei ein besonderes Augenmerk, aber auch Vorerkrankun-gen, Komplikationen, Substitutionen w{\"a}hrend der Therapie und weitere Parameter wurden f{\"u}r jeden Patienten individuell ermittelt und tabellarisch festgehalten. Insgesamt verstarben davon 125 Patienten (72,7\%), 47 Patienten (27,3\%) {\"u}berlebten und konnten entlassen werden. Bei 24 der 125 verstorbenen Patienten (14\%) konnte zwar ein Weaning vom System erfolgreich durchgef{\"u}hrt werden (>24h), sie verstarben jedoch w{\"a}hrend des anschließenden station{\"a}ren Aufenthaltes. Bei den pr{\"a}insertionell erhobenen Parametern waren der BMI und der Euroscore II bei verstorbenen Patienten signifikant h{\"o}her, ebenso wie die Cross-Clamp-Zeit und der SO-FA-Score. F{\"u}r die Laborwerte an ECMO ergaben sich f{\"u}r den Serumlaktatspiegel und die Throm-bozytenanzahl der Patienten die signifikantesten Unterschiede. Auch andere Laborparame-ter erwiesen sich in beiden Gruppen als signifikant unterschiedlich: Insbesondere der Quick Wert der {\"u}berlebenden Patienten war zu Beginn signifikant h{\"o}her. Auch der Fibri-nogenspiegel der Gruppe der {\"u}berlebenden Patienten lag ab der 12 Stunden Marke signi-fikant h{\"o}her. Verstorbene Patienten erhielten mehr Blutpr{\"a}parate als {\"U}berlebende. Außerdem f{\"u}hrte ein dialysepflichtiges Nierenversagen im Laufe der Therapie zu signifikant schlechterem Out-come. Wider Erwarten waren w{\"a}hrend der Therapie auftretende Blutungskomplikationen nicht mit schlechterem Outcome assoziiert. Jedoch konnte bei Auftritt von Thromben im Sys-tem, die einen Austausch des Oxygenators/ECMO-Systems n{\"o}tig machten, sowie Magen-Darm-Isch{\"a}mien und Kompartmentsyndrom ein klarer {\"U}berlebensnachteil erfasst werden. Abschließend ließ sich mittels multivariater logistischer Regression zeigen, dass der SO-FA-Score, der Serumlaktatspiegel und die Thrombozytenanzahl sowie eine adjuvante I-ABP Implantation und der Bedarf einer Nierenersatztherapie den gr{\"o}ßten Einfluss auf das {\"U}berleben der Patienten hatten.},
  subject      = {ECMO},
  language  = {de}
}
@article{KoehlerAdamFussetal.2022,
  author    = {Koehler, Viktoria Florentine and Adam, Pia and Fuss, Carmina Teresa and Jiang, Linmiao and Berg, Elke and Frank-Raue, Karin and Raue, Friedhelm and Hoster, Eva and Kn{\"o}sel, Thomas and Schildhaus, Hans-Ulrich and Negele, Thomas and Siebolts, Udo and Lorenz, Kerstin and Allelein, Stephanie and Schott, Matthias and Spitzweg, Christine and Kroiss, Matthias},
  title     = {Treatment of RET-positive advanced medullary thyroid cancer with multi-tyrosine kinase inhibitors — a retrospective multi-center registry analysis},
  series = {Cancers},
  volume    = {14},
  journal   = {Cancers},
  number    = {14},
  issn      = {2072-6694},
  doi       = {10.3390/cancers14143405},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-281776},
  year      = {2022},
  abstract  = {Background: RET (rearranged during transfection) variants are the most prevalent oncogenic events in medullary thyroid cancer (MTC). In advanced disease, multi-tyrosine kinase inhibitors (MKIs) cabozantinib and vandetanib are the approved standard treatment irrespective of RET status. The actual outcome of patients with RET-positive MTC treated with MKIs is ill described. Methods: We here retrospectively determined the RET oncogene variant status with a targeted DNA Custom Panel in a prospectively collected cohort of 48 patients with advanced MTC treated with vandetanib and/or cabozantinib at four German referral centers. Progression-free survival (PFS) and overall survival (OS) probabilities were estimated using the Kaplan-Meier method. Results: In total, 44/48 (92\%) patients had germline or somatic RET variants. The M918T variant was found in 29/44 (66\%) cases. In total, 2/32 (6\%) patients with a somatic RET variant had further somatic variants, while in 1/32 (3\%) patient with a germline RET variant, additional variants were found. Only 1/48 (2\%) patient had a pathogenic HRAS variant, and no variants were found in 3 cases. In first-line treatment, the median OS was 53 (95\% CI (95\% confidence interval), 32-NR (not reached); n = 36), and the median PFS was 21 months (12-39; n = 33) in RET-positive MTC patients. In second-line treatment, the median OS was 18 (13-79; n = 22), and the median PFS was 3.5 months (2-14; n = 22) in RET-positive cases. Conclusions: RET variants were highly prevalent in patients with advanced MTC. The treatment results in RET-positive cases were similar to those reported in unselected cohorts.},
  language  = {en}
}
@article{MerzenichBaakenSchmidtetal.2022,
  author    = {Merzenich, Hiltrud and Baaken, Dan and Schmidt, Marcus and Bekes, Inga and Schwentner, Lukas and Janni, Wolfgang and Woeckel, Achim and Bartkowiak, Detlef and Wiegel, Thomas and Blettner, Maria and Wollschl{\"a}ger, Daniel and Schmidberger, Heinz},
  title     = {Cardiac late effects after modern 3D-conformal radiotherapy in breast cancer patients: a retrospective cohort study in Germany (ESCaRa)},
  series = {Breast Cancer Research and Treatment},
  volume    = {191},
  journal   = {Breast Cancer Research and Treatment},
  number    = {1},
  issn      = {0167-6806},
  doi       = {10.1007/s10549-021-06412-3},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-308606},
  pages     = {147-157},
  year      = {2022},
  abstract  = {Purpose Radiotherapy (RT) was identified as a risk factor for long-term cardiac effects in breast cancer patients treated until the 1990s. However, modern techniques reduce radiation exposure of the heart, but some exposure remains unavoidable. In a retrospective cohort study, we investigated cardiac mortality and morbidity of breast cancer survivors treated with recent RT in Germany. Methods A total of 11,982 breast cancer patients treated between 1998 and 2008 were included. A mortality follow-up was conducted until 06/2018. In order to assess cardiac morbidity occurring after breast cancer treatment, a questionnaire was sent out in 2014 and 2019. The effect of breast cancer laterality on cardiac mortality and morbidity was investigated as a proxy for radiation exposure. We used Cox Proportional Hazards regression analysis, taking potential confounders into account. Results After a median follow-up time of 11.1 years, there was no significant association of tumor laterality with cardiac mortality in irradiated patients (hazard ratio (HR) for left-sided versus right-sided tumor 1.09; 95\% confidence interval (CI) 0.85-1.41). Furthermore, tumor laterality was not identified as a significant risk factor for cardiac morbidity (HR = 1.05; 95\%CI 0.88-1.25). Conclusions Even though RT for left-sided breast cancer on average incurs higher radiation dose to the heart than RT for right-sided tumors, we found no evidence that laterality is a strong risk factor for cardiac disease after contemporary RT. However, larger sample sizes, longer follow-up, detailed information on individual risk factors and heart dose are needed to assess clinically manifest late effects of current cancer therapy.},
  language  = {en}
}